AUSTRALIAN CANCER DRUG SECURES $730M DEAL

Written on the 1 February 2016

AUSTRALIAN CANCER DRUG SECURES $730M DEAL

A NEW cancer drug developed in Australia has been licensed to US pharmaceutical company Merck in a $730 million deal.

Merck will advance the drug to clinical trials, in a bid to commercialise the cancer and non-cancer blood disorder treatment worldwide.

The financial returns will be shared between the Cancer Therapeutics CRC and its research partners CSIRO, Monash University, Peter MacCallum Cancer Centre and the Walter and Eliza Hall Insititute, as well as the Wellcome Trust and Cancer Research Technology in the UK.

CSIRO research partner Dr Tom Peat says the drug is designed to inhibit the protein PRMT5, which is linked to a range of cancers including mantle cell lymphoma, lung cancer, breast cancer and colorectal cancer.

"Patients who have these types of cancers often have high levels of this protein, which is unfortunately also linked to poor survival rates," Dr Peat says.

"Using our recombinant protein production facilities, we were able to produce samples of these proteins, crystallise them for structure based drug design and support the consortium's pre-commercial investigations and trials.

"Access to high quality protein is absolutely critical in structural biology approaches to drug discovery, and CSIRO is pleased to be able to contribute this key capability."

He says the research consortium was able to develop a drug that binds to this protein, allowing it to target cancerous cells.

PRMT5 inhibitors also have the ability to switch on important genes in the development of blood, which could provide disease-modifying treatment options for patients with blood disorders like sickle cell disease and beta thalassemia.

"We're thrilled to be part of this development, which has the potential to make a real difference for patients here in Australia and around the globe," Dr Peat says.

 


Latest News

SUPREME COURT ORDERS OCTAVIAR GROUP TO WIND UP

THE Queensland Supreme Court has ordered the Octaviar Group of companies (formerly known as MFS Group) to be wound...

CEOS BRAVE THE COLD TO RAISE $1.4 MILLION FOR THE HOMELESS

MORE than 400 executives confronted the cold last night in the annual Vinnies CEO sleepout, which took place benea...

JENNIFER WESTACOTT ON BANK TAX: IT EXPOSES GOVERNMENT "DESPERATION"

South Australia's new bank levy exposes the desperation of a government that is unable to get its own budget and ...

BASKETBALL'S COMEBACK CONTINUES WITH NBL CLUBS TO FACE OFF AGAINST CHINA'S NATIONAL TEAM

THE RESURGENCE of Australia's National Basketball League (NBL) continues with China's national team to play t...

Related News

BASKETBALL'S COMEBACK CONTINUES WITH NBL CLUBS TO FACE OFF AGAINST CHINA'S NATIONAL TEAM

THE RESURGENCE of Australia's National Basketball League (NBL) continues with China's national team to play t...

DOMESTIC TOURISM IN AUSTRALIA BREAKS RECORDS, INJECTS $61.7 BILLION INTO NATIONAL ECONOMY

DOMESTIC Australian tourists have spent a record breaking $61.7 billion on intra and interstate travel this year, acc...

THE DOCTORS WHO PLUNGED INTO THE SHARK TANK AND SURVIVED WITH A $500,000 INVESTMENT

THEIR mission is to change the face of cancer care with an app that empowers and connects patients and care givers...

IMF BRACES FOR BIG LOSS FOLLOWING WITHDRAWAL FROM SPOTLESS CLASS ACTION

LITIGATION fund IMF Bentham (ASX: IMF) is set to lose as much as half a million dollars after it ceases funding one o...

BOOK YOUR FUNCTION SPACE HERE

 

 

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter